Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

RCT (n=402) found that addition of albiglutide to optimised basal insulin glargine and lispro resulted in 54% no longer requiring prandial insulin. Prandial insulin dose was 62 units/day lower for triple therapy vs optimised basal insulin glargine & lispro alone (p<0.0001).


Diabetes Care